EGFR and Hypokalemia: Analysis based on the types of targeted therapies indicated the pooled incidence of hypokalemia varied from 1% (95% CI: 0%, 3%) in the EGFR inhibitors group to 26% (95% CI: 23%, 29%) in the combination of VEGF and EGFR inhibitors and chemotherapy group (heterogeneity between groups: p < 0.01) (Supplementary Figure 14).